• Home
  • About Us
    • Member Directory
    • Contact Us
  • Blogs
    • Scientific Blogs
      • Technology
      • Environment
      • Health
    • Infinity Explorer
    • Traveler Book
    • Life Around
  • Publication
  • Scientific Advisory
  • Project
    • Future Projects
    • Ongoing Projects
    • Previous Projects
  • Services
    • Language Programs
    • Latest Software
    • Environmental Consultancy
    • Internship
    • Exercise
  • Career
    • Masters
    • PHDs
    • Postdoctorals
    • Travel Grants
    • Others

Stem cell therapy protects against the side effects of cancer drugs

Stem cell therapy protects against the side effects of cancer drugs

cancer drugs

Share:

Twitter
Tweet
LinkedIn
Share
Facebook
fb-share-icon
WeChat
Follow by Email
Hardin Bitsky

Hardin Bitsky

Mr. Hardin, a future doctor of pharmacy, provides services as a content writer for scientific and technical niches.

Immune checkpoint inhibitors (cancer drugs) are widely used to treat a variety of cancers; however, one serious side effect is the onset of type 1 diabetes. Now, researchers from Osaka University have discovered that stem cell therapy may protect against such side effects.

One strategy by which tumor cells evade recognition by the immune system is by upregulating factors that interfere with immune cell signaling—a process known as immune checkpoint. For example, the upregulation of programmed death-ligand 1 (PD-L1) leads to increased binding to its receptor (PD-1) on T cells of the immune system, inhibiting T cell activation. The therapeutic use of immune checkpoint inhibitors can reverse these effects, restoring immune system surveillance and tumor cell killing. However, these anti-cancer drugs are accompanied by autoimmune side effects, including the onset of type 1 diabetes.

Type 1 diabetes is a serious autoimmune disease that develops when the level of insulin produced by the islets of Langerhans in the pancreas drops below the required threshold, resulting in the body’s inability to control blood sugar levels. Such patients are dependent on insulin therapy. When insulin-producing cells are completely lost, the control of blood sugar levels becomes severely compromised, resulting in clinical complications, impaired quality of life, and a poor prognosis. Strategies for the prevention or cure of type 1 diabetes are currently lacking.

Mesenchymal stem cell (MSC) therapy is the most commonly used type of cell therapy. MSCs secrete factors that contribute to tissue regeneration, anti-fibrosis activity, and modulation of immune functions.

In the recent study at Osaka University, researchers showed that MSCs have therapeutic potential against immune-related adverse events. As Emi Kawada-Horitani, the lead author of the study, explains “We examined whether systemic MSC treatment could prevent the development of type 1 diabetes in a mouse model. First, we induced diabetes in the mice by administering a purified PD-L1 monoclonal antibody. Then, we injected human adipose-derived MSCs and analyzed immune cells in the pancreatic secretions,” Kawada-Horitani continues, “Inhibition of the PD-1/PD-L1 interaction with an anti-PD-L1 antibody resulted in a diabetes incidence of 64% among the mice, compared with 19% when the mice were also administered MSCs.”

Inhibition of the cancer drugs PD-1/PD-L1 interaction causes various changes in the immune system—most notably, the massive accumulation of immune cells (particularly macrophages) in the islets of Langerhans in the pancreas, disrupting insulin production.

“We found that MSCs effectively prevented this influx of immune cells,” corresponding author Shunbun Kita explains, “thereby avoiding the detrimental effects on pancreatic cells.” They further showed that MSCs secrete factors (such as exosomes) that protect the pancreatic cells against immune attack.

Their findings suggest that MSC transplantation can prevent the incidence of diabetes associated with immune checkpoint cancer therapy and is therefore worthy of consideration as a new type of adjuvant cell therapy. The study appears in Diabetologia.

Related article:

Hope for 1st vaccine against virus driving ‘mono,’ cancers and maybe MS

Starting screening before age 50 is found to significantly reduce the risk and incidence of colorectal cancer in women

PrevPreviousObesity linked to higher risk of broken bones in women
NextTwo new Epstein-Barr virus vaccines induce neutralizing antibodies in miceNext

LATEST Blogs

Breakfast and health problems

Skipping Breakfast May Increase a Child’s Risk of Psychosocial Health Problems

September 7, 2022
James webb telescope

NASA’s Webb Space Telescope Captures a Cosmic Tarantula

September 7, 2022

Worse Than Smoking – Bad Sleep Can Worsen Lung Disease

August 31, 2022
Nanotechnology

Dr. Muhammad Adeel Addressed the International Con-ference as keynote speaker

August 23, 2022
Benefits of Mushrooms

Top 10 Health Benefits of Mushrooms, the Ultimate Superfood

August 18, 2022

New Way Invented To Produce Oxygen on Mars for Future Explorers

August 18, 2022

Evidence of Unprecedented Modern Sea-Level Rise Found in Ancient Caves

August 18, 2022

Research Shows Salt Substitutes Lower Risk of Heart Attack/Stroke and Death

August 13, 2022
covid symptoms

Hair Loss and Sexual Dysfunction Join Fatigue and Brain Fog in List of Long COVID Symptoms

August 13, 2022
protein

Most People Are Eating Too Much Protein – And It Has Serious Consequences

August 13, 2022

Categories

  • Scientific Blogs
  • Infinity Explorer
  • Traveler Book
  • Life Around

If you have tried to make a difference and you believe you deserve to be acknowledge, then please submit your story to us

Subscribe

Virtual Green Innovation Hub (VGI-H) is an emerging platform for young researchers which works as a bridge between You and the society.

Useful Links

Home
About us
Blogs

Subscribe Now

Don’t miss our future updates! Get Subscribed Today!

Copyright ©2022 Virtual Green Innovation Hub. All Rights Reserved.

Don’t miss our future updates. Get Subscribed Today!